Cargando…
Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies
The World Health Organization recommends same-day initiation of antiretroviral therapy (ART) for all persons diagnosed with HIV and ready to start treatment. Evidence, mainly from randomized trials, indicates offering same-day ART increases engagement in care and viral suppression during the first y...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573746/ https://www.ncbi.nlm.nih.gov/pubmed/37229594 http://dx.doi.org/10.1093/cid/ciad317 |
_version_ | 1785120533440888832 |
---|---|
author | Labhardt, Niklaus Daniel Brown, Jennifer Anne Sass, Nikita Ford, Nathan Rosen, Sydney |
author_facet | Labhardt, Niklaus Daniel Brown, Jennifer Anne Sass, Nikita Ford, Nathan Rosen, Sydney |
author_sort | Labhardt, Niklaus Daniel |
collection | PubMed |
description | The World Health Organization recommends same-day initiation of antiretroviral therapy (ART) for all persons diagnosed with HIV and ready to start treatment. Evidence, mainly from randomized trials, indicates offering same-day ART increases engagement in care and viral suppression during the first year. In contrast, most observational studies using routine data find same-day ART to be associated with lower engagement in care. We argue that this discrepancy is mainly driven by different time points of enrollment, leading to different denominators. While randomized trials enroll individuals when tested positive, most observational studies start at the time point when ART is initiated. Thus, most observational studies omit those who are lost between diagnosis and treatment, thereby introducing a selection bias in the group with delayed ART. This viewpoint article summarizes the available evidence and argues that the benefits of same-day ART outweigh a potential higher risk of attrition from care after ART initiation. |
format | Online Article Text |
id | pubmed-10573746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105737462023-10-14 Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies Labhardt, Niklaus Daniel Brown, Jennifer Anne Sass, Nikita Ford, Nathan Rosen, Sydney Clin Infect Dis Viewpoints Article The World Health Organization recommends same-day initiation of antiretroviral therapy (ART) for all persons diagnosed with HIV and ready to start treatment. Evidence, mainly from randomized trials, indicates offering same-day ART increases engagement in care and viral suppression during the first year. In contrast, most observational studies using routine data find same-day ART to be associated with lower engagement in care. We argue that this discrepancy is mainly driven by different time points of enrollment, leading to different denominators. While randomized trials enroll individuals when tested positive, most observational studies start at the time point when ART is initiated. Thus, most observational studies omit those who are lost between diagnosis and treatment, thereby introducing a selection bias in the group with delayed ART. This viewpoint article summarizes the available evidence and argues that the benefits of same-day ART outweigh a potential higher risk of attrition from care after ART initiation. Oxford University Press 2023-05-25 /pmc/articles/PMC10573746/ /pubmed/37229594 http://dx.doi.org/10.1093/cid/ciad317 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Viewpoints Article Labhardt, Niklaus Daniel Brown, Jennifer Anne Sass, Nikita Ford, Nathan Rosen, Sydney Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies |
title | Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies |
title_full | Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies |
title_fullStr | Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies |
title_full_unstemmed | Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies |
title_short | Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies |
title_sort | treatment outcomes after offering same-day initiation of human immunodeficiency virus treatment—how to interpret discrepancies between different studies |
topic | Viewpoints Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573746/ https://www.ncbi.nlm.nih.gov/pubmed/37229594 http://dx.doi.org/10.1093/cid/ciad317 |
work_keys_str_mv | AT labhardtniklausdaniel treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies AT brownjenniferanne treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies AT sassnikita treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies AT fordnathan treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies AT rosensydney treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies |